Karyopharm Therapeutics (KPTI) Interest & Investment Income (2013 - 2025)
Karyopharm Therapeutics (KPTI) reported Interest & Investment Income of $607000.0 for Q4 2025, down 59.04% on a YoY basis from $1.5 million in Q4 2024, and up 9.76% quarter-over-quarter from $553000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Interest & Investment Income (2013 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Interest & Investment Income for 13 years, with the latest figure at $607000.0 in Q4 2025.
- For the quarter ending Q4 2025, Interest & Investment Income fell 59.04% year-over-year to $607000.0; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (down 62.53% YoY), and the FY2025 full-year result was $2.8 million, down 62.53% from the prior year.
- Interest & Investment Income for Q4 2025 stood at $607000.0, up from $553000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $2.8 million in Q1 2023, with the low at $55000.0 in Q4 2021.
- Historically, Interest & Investment Income has averaged $1.2 million across 5 years, with a median of $829000.0 in 2022.
- Annual changes were most pronounced in 2021 — Interest & Investment Income plunged 86.11% — and 2023, when it surged 3750.0%.
- Karyopharm Therapeutics' Interest & Investment Income stood at $55000.0 in 2021, then jumped by 2325.45% to $1.3 million in 2022, then soared by 88.91% to $2.5 million in 2023, then tumbled by 41.19% to $1.5 million in 2024, then tumbled by 59.04% to $607000.0 in 2025.
- The last three Interest & Investment Income figures came in at $607000.0 (Q4 2025), $553000.0 (Q3 2025), and $613000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -14.79 Mn |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | 607,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 607,000.00 |
| Sep 30, 2025 | 553,000.00 |
| Jun 30, 2025 | 613,000.00 |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 2.52 Mn |
| Sep 30, 2023 | 2.75 Mn |
| Jun 30, 2023 | 2.82 Mn |
| Mar 31, 2023 | 2.85 Mn |
| Dec 31, 2022 | 1.33 Mn |
| Sep 30, 2022 | 658,000.00 |
| Jun 30, 2022 | 293,000.00 |
| Mar 31, 2022 | 74,000.00 |
| Dec 31, 2021 | 55,000.00 |
| Sep 30, 2021 | 98,000.00 |
| Jun 30, 2021 | 165,000.00 |
| Mar 31, 2021 | 264,000.00 |